Zacks Research Predicts Clorox’s FY2025 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX) – Equities researchers at Zacks Research decreased their FY2025 earnings per share (EPS) estimates for shares of Clorox in a report released on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $7.09 for the year, down from their previous estimate of $7.15. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q4 2026 earnings at $2.11 EPS and FY2027 earnings at $7.34 EPS.

Other research analysts have also issued research reports about the company. Morgan Stanley reduced their target price on Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. Citigroup reduced their target price on Clorox from $165.00 to $150.00 and set a “neutral” rating for the company in a report on Monday, April 14th. Barclays reduced their target price on Clorox from $134.00 to $129.00 and set an “underweight” rating for the company in a report on Wednesday, May 7th. DA Davidson cut their price objective on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Finally, Evercore ISI set a $140.00 price objective on Clorox and gave the stock an “underperform” rating in a report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $151.23.

Clorox Trading Down 0.7%

Shares of CLX opened at $130.93 on Thursday. The business has a 50-day moving average of $139.91 and a 200 day moving average of $152.60. Clorox has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The firm has a market cap of $16.14 billion, a P/E ratio of 35.77, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.74 billion. During the same period last year, the business posted $1.71 EPS. The company’s revenue was down 8.0% compared to the same quarter last year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, May 9th. Investors of record on Wednesday, April 23rd were given a $1.22 dividend. The ex-dividend date was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.73%. Clorox’s payout ratio is 87.61%.

Insider Buying and Selling

In other news, Director Pierre R. Breber bought 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $546,280. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Clorox

A number of hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its position in Clorox by 70.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 2,652 shares of the company’s stock worth $391,000 after buying an additional 1,094 shares during the last quarter. Belpointe Asset Management LLC boosted its stake in shares of Clorox by 6.9% during the first quarter. Belpointe Asset Management LLC now owns 3,181 shares of the company’s stock valued at $469,000 after purchasing an additional 206 shares during the period. Intech Investment Management LLC boosted its stake in shares of Clorox by 25.4% during the first quarter. Intech Investment Management LLC now owns 68,261 shares of the company’s stock valued at $10,051,000 after purchasing an additional 13,833 shares during the period. Focus Partners Wealth boosted its stake in shares of Clorox by 34.4% during the first quarter. Focus Partners Wealth now owns 14,936 shares of the company’s stock valued at $2,199,000 after purchasing an additional 3,824 shares during the period. Finally, Integrity Alliance LLC. purchased a new stake in shares of Clorox during the first quarter valued at approximately $419,000. Institutional investors own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.